PROCEPT BioRobotics Corporation (PRCT) Guidance & Earnings Results
On 2026-08-04 PROCEPT BioRobotics Corporation reaffirmed guidance: "Revenue guidance $390-410M; U.S. procedure guidance raised to…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PRCTPROCEPT BioRobotics CorporationFollow PRCT — free
—
Price chart with a free account
- Market cap
- 1.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 10 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 4 Aug 26 | Reaffirmed | Revenue guidance $390-410M; U.S. procedure guidance raised to 54,000-56,000 · full year |
| 29 Apr 26 | Reaffirmed | FY2026 revenue guidance $390-410M; gross margin ~65%; adjusted EBITDA loss $30-17M · full year |
| 4 Nov 25 | Raised | FY2026 revenue guidance $410-430M (26-32% growth); FY2025 reiterated at ~$325.5M |
| 6 Aug 25 | Raised | FY2025 revenue raised to ~$325.5M from $323.0M; gross margin ~64.5%; total operating expense ~$302.0M from $300.0M; Adjusted EBITDA loss ~($35.0)M · full year |
PROCEPT BioRobotics Corporation — questions
- What guidance did PROCEPT BioRobotics Corporation give?
- On 2026-08-04: "Revenue guidance $390-410M; U.S. procedure guidance raised to 54,000-56,000"
- When does PROCEPT BioRobotics Corporation report earnings?
- PROCEPT BioRobotics Corporation's next earnings report is expected on 2026-11-04.
Every figure on this page comes from PROCEPT BioRobotics Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.